Delivery Order SPE2D020D0005-SPE2D325F308F
Award Date 8/11/25
Potential Completion Date 8/14/25
Potential Value $1.6K
Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Congers, NY 10920, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The U.S. Department of Defense's Medical Supply Chain awarded a delivery order valued at $1,184.50 to Chartwell RX LLC for the supply of Ondansetron ODT 4 mg tablets in quantities of 30 units. The award was issued on July 30, 2025, with an ultimate completion date of August 4, 2025, under a firm fixed-price contract type with no set-aside designation. Chartwell RX LLC, a pharmaceutical company headquartered in Congers, New York, will fulfill this order from its place of performance at the same...
- The U.S. Department of Defense Medical Supply Chain awarded a delivery order to Chartwell RX LLC on August 4, 2025, for the supply of Ondansetron orally disintegrating tablets in 4 milligram strength, with a ceiling value of $1,066.05 and an ultimate completion date of August 7, 2025. This firm fixed-price delivery order was issued without a set-aside designation and represents a continuation of the government's pharmaceutical supply chain through an Indefinite Delivery Vehicle contract...
- The U.S. Department of Defense's Medical Supply Chain awarded a delivery order to Chartwell RX LLC on September 2, 2025, for the supply of Ondansetron Orally Disintegrating Tablets (ODT) 4 mg in quantities of 30 tablets, with a ceiling value of $1,184.50. This is a firm fixed-price delivery order with an ultimate completion date of September 5, 2025, and carries no set-aside designation. The order will be fulfilled at Chartwell RX's facility located in Congers, New York. Chartwell RX LLC is an...
- The U.S. Department of Defense Medical Supply Chain awarded a delivery order to Chartwell RX LLC on August 20, 2025, for the supply of Ondansetron ODT (orally disintegrating tablets) 4 mg in quantities of 30 tablets. This firm fixed-price delivery order, valued at $1,184.50, represents a continuation of pharmaceutical supply support to federal military and veteran healthcare services. The contract carries no set-aside designation and is set for completion by August 25, 2025, with fulfillment...
- The U.S. Department of Defense, through its Medical Supply Chain division, awarded a delivery order to Chartwell RX LLC for the supply of Ondansetron ODT (Orally Disintegrating Tablets) 4 mg in quantities of 30 tablets. This firm fixed-price delivery order, valued at $1,302.95, was issued on September 3, 2025, with an ultimate completion date of September 8, 2025. The contract carries no set-aside designation and will be performed at Chartwell RX's facility in Congers, New York. Ondansetron is a...
- The U.S. Defense Department's Medical Supply Chain awarded a $1,184.50 firm fixed-price delivery order to Chartwell RX LLC on September 3, 2025, for the supply of Ondansetron ODT (orally disintegrating tablets) 4 mg in a quantity of 30 tablets. The delivery order, which carries an ultimate completion date of September 8, 2025, was issued without a set-aside designation. Chartwell RX LLC, a pharmaceutical manufacturer and distributor headquartered in Congers, New York, has been registered in...
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded a delivery order valued at $3,671.95 to Chartwell RX LLC on August 27, 2025, for the supply of Ondansetron ODT (orally disintegrating tablets) 4 mg in a quantity of 30 tablets. This contract is structured as a firm fixed-price delivery order with an ultimate completion date of September 2, 2025, and will be fulfilled from Chartwell RX's facility in Congers, New York. No set-aside designation was applied to this award. Ondansetron...
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded a delivery order to Chartwell RX LLC on September 2, 2025, for the supply of Ondansetron ODT (orally disintegrating tablets) 4 mg in quantities of 30 tablets. This is a firm fixed-price delivery order with a ceiling value of $3,553.50 and an ultimate completion date of September 5, 2025. The contract was awarded without a set-aside designation and will be performed at Chartwell RX's facility in Congers, New York. Ondansetron is...
- This is a $1,776.75 firm fixed price delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Chartwell RX LLC, a pharmaceutical company based in Congers, New York. The contract is for the supply of 4 mg ondansetron orally disintegrating tablets in 30-count packages. This delivery order is issued under Chartwell RX's existing Indefinite Delivery Contract (SPE2D020D0005) with DLA, which enables the company to manufacture and distribute a broad range of...
- This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Chartwell RX LLC, a pharmaceutical company based in Congers, New York. The contract, valued at $1,184.50, is a delivery order for the supply of 4,564,381,636 units of ondansetron ODT (orally disintegrating tablet) 4 mg, packaged in 30s. The contract is a firm fixed price agreement and has an ultimate completion date of April 29, 2024. Chartwell RX LLC is the prime contractor for this award,...